2 results
Approved WMOPending
- The primary objective is to determine the dose limiting toxicity and the maximum tolerated dose and recommended dose of the combination of temsirolimus weekly and nelfinavir orally BID to patients with advanced solid tumors.- Secondary objective…
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…